Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Expression of carcinoembryonic antigen in peripheral- or central-located small cell lung cancer: Its clinical significance
Autore:
Bandoh, S; Fujita, J; Ueda, Y; Fukunaga, Y; Dohmoto, K; Hojo, S; Yang, Y; Yamaji, Y; Takahara, J; Ishida, T;
Indirizzi:
Kagawa Med Univ, Dept Internal Med 1, Miki, Kagawa 7610793, Japan Kagawa Med Univ Miki Kagawa Japan 7610793 1, Miki, Kagawa 7610793, Japan
Titolo Testata:
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 7, volume: 31, anno: 2001,
pagine: 305 - 310
SICI:
0368-2811(200107)31:7<305:EOCAIP>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEURON-SPECIFIC ENOLASE; BRONCHOGENIC-CARCINOMA; SUBTYPES; MARKER; CEA;
Keywords:
lung cancer; small cell carcinoma; peripheral; central; carcinoembryonic antigen;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Bandoh, S Kagawa Med Univ, Dept Internal Med 1, Miki, Kagawa 7610793, Japan Kagawa Med Univ Miki Kagawa Japan 7610793 Kagawa 7610793, Japan
Citazione:
S. Bandoh et al., "Expression of carcinoembryonic antigen in peripheral- or central-located small cell lung cancer: Its clinical significance", JPN J CLIN, 31(7), 2001, pp. 305-310

Abstract

Background: Small cell lung cancer (SCLC) has a higher percentage of hilarmasses than other histological types of lung cancer. The primary site is usually adjacent to the hilum, but we often observe primary sites in the peripheral lung field. In this study, our objectives were to elucidate whetherperipheral-located small cell lung cancer (PSCLC) is an independent entityand whether it differs clinically from central-located small cell lung cancer (CSCLC). Methods: We reviewed the clinical and pathological features of 52 patientstreated at Kagawa Medical University Hospital between 1987 and 1996 with adiagnosis of SCLC. We defined CSCLC as a tumor whose primary site is located in the segmental bronchi or more proximally and PSCLC as a tumor locateddistal to the subsegmental bronchi. Twenty-one PSCLC patients and 31 CSCLCpatients were identified. Kaplan-Meier survival curves were constructed and comparisons were made between PSCLC and CSCLC by the log-rank test. The carcinoembryonic antigen (CEA) level was also evaluated in each group. Results: Although the percentage of limited disease (LD) in the patients with PSCLC was higher than that in the patients with CSCLC, the 3-year survival rate of PSCLC tended to be worse than that of CSCLC (9% for patients with PSCLC and 29% for those with CSCLC). Survival curves of patients with PSCLC also tended to be worse than those of patients with CSCLC, not only in the limited disease group but also in the extensive disease (ED) group. In addition, the mean CEA value in patients with PSCLC was higher than that inpatients with CSCLC (p < 0.001), whereas the neuron specific enolase (NSE)level was not significantly different between PSCLC and CSCLC. The median survival of patients with pretherapeutic CEA titers of <greater than>5 ng/ml was significantly shorter than that in patients with CEA levels <5 ng/ml. Conclusion: These findings suggest that the survival of SCLC patients witha high CEA level was significantly shorter than that of patients with a low CEA level. In addition, CEA levels in PSCLC patients were significantly higher than those in CSCLC patients. However, the survivals of LD or ED patients with PSCLC and CSCLC were not statistically different.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/04/20 alle ore 15:27:38